Assessment of drug effects on blood pressure and pulse pressure using clinic, home and ambulatory measurements

Journal of Human Hypertension

Volumn 16, Issue 10, 2002, Pages 729-735

  Stergiou, G S ^a   Efstathiou, S P ^a   Skeva, I I ^a   Baibas, N M ^a   Kalkana, C B ^a   Mountokalakis, T D ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Ambulatory pulse pressure; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Home blood pressure; Pulse pressure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN;

ADULT; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HOME; HUMAN; HYPERTENSION; MALE; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-OVER STUDIES; FEMALE; HOME CARE SERVICES; HUMANS; HYPERTENSION; LISINOPRIL; LOSARTAN; MALE; OFFICE VISITS; PULSE; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 0036813050     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001477     Document Type: Article

References (33)

1. James GD et al. The reproducibility of average ambulatory, home, and clinic pressures. Hypertension 1988; 1: 545-549.
2. Stergiou GS et al. Reproducibility of home, ambulatory and clinic blood pressure: Implications for the design of trials for the assessment of antihypertensive drug efficacy. Am J Hypertens 2002; 15: 101-104.
3. Conway J, Coats A. Value of ambulatory blood pressure monitoring in clinical pharmacology. J Hypertens 1989; 7(Suppl 3): S29-S32.
4. Trazzi S et al. Reproducibility of non-invasive and intra-arterial blood pressure monitoring: Implications for studies on antihypertensive drugs. J Hypertens 1991; 9: 115-119.
5. Stergiou GS, Skeva II, Zourbaki AS, Mountokalakis TD. Self monitoring of blood pressure at home: How many measurements are needed? J Hypertens 1998; 16: 725-731.
6. Stergiou GS, Zourbaki AS, Skeva II, Mountokalakis TD. White coat effect detected using self-monitoring of blood pressure at home: Comparison with ambulatory blood pressure. Am J Hypertens 1998; 11: 820-827.
7. Vaur L et al. Superiority of home blood pressure measurements over office measurements for testing antihypertensive drugs. Blood Press Monit 1998; 3: 107-114.
8. Asmar R et al. Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations. Am J Hypertens 2001; 14: 91-97.
9. Benetos A et al. Pulse pressure: A predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410-1415.
10. Kostis JB et al. Association of increased pulse pressure with the development of heart failure in SHEP. Systolic Hypertension in the Elderly (SHEP) Cooperative Research Group. Am J Hypertens 2001; 14: 793-803.
11. Blather J et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085-1089.
12. Verdecchia P et al. Ambulatory pulse pressure: A potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32: 983-988.
13. Asmar R, Lacourciere Y. A new approach to assessing antihypertensive therapy: Effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens 2000; 18: 1683-1690.
14. Asmar R, Safar M, Queneau P. Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. Am J Hypertens 2001; 14: 546-552.
15. Safar ME, Rudnichi A, Asmar R. Drug treatment of hypertension: The reduction of pulse pressure does not necessarily parallel that of systolic and diastolic blood pressure. J Hypertens 2000; 18: 1159-1163.
16. O'Brien E et al. An outline of the revised British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J Hypertens 1993; 11: 677-679.
17. O'Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: The Omron HEM-705CP, Philips HP5332 and Nissei DS-175. Blood Press Monit 1996; 1: 55-61.
18. Altman DG. Analysis of crossover trials. In: Practical Statistics for Medical Research. Chapman & Hall: London, 1991; pp 467-471.
19. Stergiou GS et al. Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response of angiotensin receptor antagonism? Am J Hypertens 2001; 14: 688-693.
20. Mansoor GA, McCabe EJ, White WB. Long-term reproducibility of ambulatory blood pressure. J Hypertens 1994; 12: 703-708.
21. Brueren MM et al. Is a series of blood pressure measurements by the general practitioner or the patient a reliable alternative to ambulatory blood pressure measurements? A study in general practice with reference to short-term and long-term between-visit variability. Am J Hypertens 1997; 10: 879-885.
22. Chatellier G et al. Home self blood pressure measurement in general practice: The SMART study. Am J Hypertens 1996; 9: 644-652.
23. Chatellier G, Day M, Bodrie G, Menard J. Feasibility study of n-of-1 trials with blood pressure self-monitoring in hypertension. Hypertension 1995; 25: 294-301.
24. Madhavan S, Choi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395-401.
25. Stergiou GS et al. Clinic, home and ambulatory pulse pressure: Comparison and reproducibility. J Hypertens 2002; in press.
26. MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observation studies corrected for the regression dilution bias. Lancet 1990; 335: 827-838.
27. James MA et al. Pulse pressure and resistance artery structure in the elderly. Hypertension 1995; 26: 301-306.
28. Bumier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
29. Stergiou GS et al. Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000; 35: 937-941.
30. O'Rourke MF. Arterial mechanics and wave reflection with antihypertensive therapy. J Hypertens 1992; 10: S43-S49.
31. Safar ME. Pulse pressure in essential hypertension: Clinical and therapeutic implications. J Hypertens 1989; 7: 769-776.
32. Klemsdal TO, Moan A, Kjeldsen SE. Effects of selective angiotensin II type 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension. Blood Press 1999; 8: 214-219.
33. Safar ME et al. Pulse pressure in sustained essential hypertension: A hemodynamic study. J Hypertens 1987; 5: 213-218.